caselaw.findlaw.com/us-3rd-circuit/1313639.html

ASTRAZENECA PHARMACEUTICALS LP. ... Alvin EMORY, Appellant v. ... of the Americans with Disabilities Act (“ADA”), 42 U.S.C. § 12101 et seq. Moving for summary judgment, AstraZeneca urged that Emory's substantive ... In all, Emory bid unsuccessfully for approximately ten internal promotions over a 12-year period.

caselaw.findlaw.com/us-3rd-circuit/1681038.html

Case opinion for US 3rd Circuit UNITED STATES SCHUMANN v. ... ASTRAZENECA PHARMACEUTICALS L.P.; Astrazeneca LP; Bristol–Myers Squibb ... 31 U.S.C. § 3729 et seq., and corresponding state laws, appeals the District Court's .... At all relevant times, BMS participated in Medicaid's Drug Rebate Program with ...

www.law360.com/cases/59e6216bb9a1b52a7e000001

Parties, docket activity and news coverage of federal case ATCHLEY et al v. ASTRAZENECA UK ... Defendant. ASTRAZENECA PHARMACEUTICALS LP ...

marcomm.mccarthy.ca/pubs/Martin_Astrazeneca_2012_ONSC_2744_CanLII.pdf

May 7, 2012 ... Wilmington, Delaware, U.S.A. AstraZeneca Pharmaceuticals is a brand name ...... information: see Huntat 980; Anderson et al. v. Wilson et al.

law.justia.com/cases/federal/appellate-courts/ca1/15-2232/15-2232-2017-05-02.html

Plaintiff appealed the district court's grant of summary judgment in favor of her former employer, AstraZeneca Pharmaceutical LP, on Plaintiff's claims that ...

www.bafirm.com/2018/08/astrazeneca-settles-texas-medicaid-fraud-suits-110m

Aug 20, 2018 ... Law360 (August 7, 2018, 8:41 PM EDT) — Pharmaceutical giant ... AstraZeneca LP et al., number D-1-GN-13-003530, and State of ... Layne D. Foote, Mark T. Lorden, Rosemarie De Souza and Kenneth McDonough, M.D. v.

www.wnylc.com/resources/courts/3rdcir.htm

John Wilson, Frank Kryjer and Donald Jones ("the appellants") were all hired by UIIS under ... Burdette Tomlin Memorial Hosp., 438 F.3d 240 (1/2006) Arnie Armstrong ... Emory v. AstraZeneca Pharmaceuticals LP, 401 F.3d 174 (3/2005) Alvin "Rob" ... of the Americans with Disabilities Act ("ADA"), 42 U.S.C. § 12101 et seq.